Transforming medicine

Publication of Annual Report and Financial Statements for the Year ended 31 December 2021

Acacia Pharma to Postpone Publication of its Results for the Full Year 2021, Scheduled on 31 March 2022

Scheme of Arrangement Information Sheet

Proposed Transaction with Eagle Pharmaceuticals, Inc. (Part 1 of 2)

Proposed Transaction with Eagle Pharmaceuticals, Inc (Part 2 of 2)

Proposed Capital Raising

Acacia Pharma Group plc - Results of Placing - EUR 27 million Raised to Invest Further in US Launch and Commercialization Activities

Acacia Pharma Group plc - Proposed Capital Raising by way of a Placing of New Ordinary Shares and Update on Early Positive Market Reception to US Launch of BARHEMSYS®

Issues of New Ordinary Shares in Connection with the Byfavo™ Acquisition

Proposed Capital Raising

Acacia Pharma Prospectus: Issue of 12,500,000 New Ordinary Shares

Acacia Pharma Group plc - Proposed Capital Raising by way of a Placing of New Ordinary Shares

Issues of New Ordinary Shares in Connection with the BYFAVO™ Acquisition

Acacia Pharma Prospectus: Issues of New Ordinary Shares in connection with the BYFAVO™ Acquisition